Market News AIOpen the app

Olema Oncology shared new research showing its KAT6A degraders work well for treating certain breast cancers.

TrialRead the original at morningstar.com
Good for OLMA

Olema reported promising activity from its drug candidates across several cancer models, and all tested groups tolerated them. The results are from tests before patient studies, so they do not yet show whether the drugs help people.

OLMA · Olema Oncology

AI read · Good for OLMA

The AI's read

The results give Olema an early sign that its drug candidates may work across different breast cancer models. The drugs were tolerated in every tested group. These tests were done before patient studies, so they do not show whether the drugs help people.

Get alerts for OLMA

Follow Olema Oncology (OLMA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OLMA
Free on the App Store and Google Play, or on the web.